Atlantic International Corp. (ATLN) Stock Analysis

Atlantic International Corp. (ATLN) Healthcare & Pipeline Overview

Atlantic International Corp. (ATLN) is a life sciences instrumentation and research services company focused on developing scientific assets and intellectual property across multiple omics fields. Their True Single Molecule Sequencing (tSMS) technology platform offers a single-molecule solution for DNA and RNA sequencing, serving research and diagnostic markets.

What Is the Investment Thesis for ATLN?

Atlantic International Corp. presents a compelling, albeit high-risk, investment opportunity within the life sciences sector. The company's tSMS technology offers a differentiated approach to DNA and RNA sequencing, potentially capturing market share in biomarker discovery and diagnostic assay development. Key value drivers include the expansion of research and development agreements, successful commercialization of the tSMS platform, and strategic partnerships with pharmaceutical and biotechnology companies. The company's current market capitalization is $73.2M. Ongoing collaborations with the FBI and Weizmann Institute of Science could validate the technology and drive adoption. However, the company's negative profit margin of -13.6% highlights the need for improved operational efficiency and revenue generation. Investors should closely monitor the company's ability to scale its operations, secure additional funding, and navigate the competitive landscape.

Based on FMP financials and quantitative analysis

ATLN Key Highlights

Market capitalization of $73.2M reflects investor valuation of Atlantic International Corp.'s technology and market potential.

• Gross margin of 10.6% indicates potential for improvement as the company scales production and optimizes cost structures.
• Profit margin of -13.6% highlights the company's current challenge in achieving profitability, requiring focus on revenue growth and expense management.
• Beta of 1.23 suggests that Atlantic International Corp.'s stock is more volatile than the overall market, indicating higher risk and potential for greater returns.
• Reverse merger with Lyneer Investments, LLC in June 2024 provides Atlantic International Corp. with access to capital and strategic resources.

Who Are ATLN's Competitors?

ATLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ATLN's Key Strengths?

Proprietary tSMS technology offers high accuracy and sensitivity.

• Research collaborations with the FBI and Weizmann Institute of Science.
• Focus on emerging market of single-molecule sequencing.
• Experienced management team with expertise in life sciences.

What Are ATLN's Weaknesses?

Negative profit margin indicates financial instability.

• Limited commercialization experience.
• Reliance on research and development agreements for revenue.
• Small market capitalization compared to competitors.

What Could Drive ATLN Stock Higher?

ATLN catalyst: Continued progress in research and development agreements with the FBI and Weizmann Institute of Science.

• Potential commercialization of diagnostic assays based on tSMS technology by 2027-2028.
• Expansion of tSMS platform applications into new research areas.
• Strategic partnerships with pharmaceutical and biotechnology companies.

What Are the Key Risks for ATLN?

Listing risk — at $0.9001 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -0.24 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established sequencing technology providers.
• Technological obsolescence of tSMS platform.
• Regulatory hurdles for diagnostic assay development.
• Economic downturn impacting research funding.
• The company's negative profit margin and need for additional funding.

What Are the Growth Opportunities for ATLN?

• Growth opportunity 1: Expansion of tSMS platform applications into new research areas, such as drug discovery and development, personalized medicine, and agricultural biotechnology. The market for genomic sequencing in drug discovery is projected to reach $12 billion by 2027, offering a significant opportunity for Atlantic International Corp. to leverage its technology and expertise. Timeline: Ongoing.
• Growth opportunity 2: Strategic partnerships with pharmaceutical and biotechnology companies to integrate tSMS technology into their research and development pipelines. These partnerships can provide Atlantic International Corp. with access to new markets, funding, and expertise. The market for research collaborations in the life sciences sector is estimated at $40 billion annually. Timeline: Ongoing.
• Growth opportunity 3: Commercialization of diagnostic assays based on tSMS technology for early detection and monitoring of diseases. Timeline: 2027-2028.
• Growth opportunity 4: Expansion of research and development agreements with government agencies and research institutions to validate and promote the adoption of tSMS technology. These agreements can provide Atlantic International Corp. with access to funding, expertise, and validation of its technology. The market for government-funded research in the life sciences sector is estimated at $50 billion annually. Timeline: Ongoing.
• Growth opportunity 5: Development of a cloud-based platform for data analysis and visualization of tSMS sequencing data. This platform can provide researchers with access to advanced analytical tools and resources, enabling them to accelerate their research and development efforts. The market for cloud-based bioinformatics solutions is projected to reach $5 billion by 2026. Timeline: 2026-2027.

What Are ATLN's Competitive Advantages?

• Proprietary True Single Molecule Sequencing (tSMS) technology.
• Research and development agreements with leading institutions.
• Expertise in single-molecule sequencing and data analysis.
• Established relationships with key customers in the life sciences sector.

What Does ATLN Do?

Founded in 2013 and formerly known as SeqLL Inc., Atlantic International Corp. rebranded in June 2024 following its acquisition by Lyneer Investments, LLC, via a reverse merger. Headquartered in Billerica, Massachusetts, the company operates as a life sciences instrumentation and research services provider. Atlantic International Corp. specializes in the development of scientific assets and novel intellectual property across multiple omics fields, including genomics and proteomics. Its core technology, the True Single Molecule Sequencing (tSMS) platform, offers a single-molecule solution for DNA and RNA sequencing. This technology enables researchers to analyze billions of single molecules in a single experiment, generating accurate and reproducible data. The company's solutions cater to a diverse range of applications, including biomarker discovery and diagnostic assay development. Atlantic International Corp. serves laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. The company also has research and development agreements with the U.S. Department of Justice's Federal Bureau of Investigation and the Weizmann Institute of Science, focusing on forensic capabilities of direct RNA sequencing and innovative single-molecule technologies, respectively.

What Products and Services Does ATLN Offer?

• Develop and commercialize the True Single Molecule Sequencing (tSMS) platform.
• Offer single-molecule solutions for DNA and RNA sequencing.
• Provide research services to universities, research centers, and government institutions.
• Develop diagnostic assays for biomarker discovery.
• Collaborate with biotechnology and pharmaceutical companies.
• Focus on scientific assets and novel intellectual property across multiple omics fields.

How Does ATLN Make Money?

• Generate revenue through sales of tSMS sequencing platforms.
• Provide sequencing services to research institutions and pharmaceutical companies.
• Earn revenue through research and development agreements.
• Commercialize diagnostic assays based on tSMS technology.

What Industry Does ATLN Operate In?

Atlantic International Corp. operates within the rapidly evolving medical diagnostics and research industry. The competitive landscape includes established players offering traditional sequencing methods and emerging companies developing innovative single-molecule technologies. Atlantic International Corp.'s tSMS platform positions it to capture a niche market segment focused on high-accuracy, single-molecule analysis. The company's success depends on its ability to demonstrate the advantages of its technology over existing solutions and secure partnerships with key stakeholders.

Who Are ATLN's Key Customers?

• Universities and academic research institutions.
• Biotechnology and pharmaceutical companies.
• Government research institutions.
• Diagnostic assay developers.

Atlantic International Corp. Financial Trajectory

Atlantic International Corp. (ATLN) reported $319.8M in revenue for Q2 FY2026, reflecting 28.0% growth compared to the prior quarter. The company recorded a net loss of $86.4M, with diluted EPS of $-1.07. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, ATLN averaged $-0.54 in diluted EPS.

Company Profile

Atlantic International Corp. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Englewood Cliffs, US. The company is led by CEO Jeffrey Jagid. ATLN has traded publicly since 2021.

How Atlantic International Corp. Is Valued

Atlantic International Corp. carries a market capitalization of $73.2M, placing it in the micro-cap category.

Return on equity for Atlantic International Corp. stands at 274.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.71 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -137.6%, the inverse of the P/E and a quick read on earnings relative to price.

Atlantic International Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.24 places it in the distress zone, a signal of elevated financial risk.

Atlantic International Corp. has missed Wall Street's EPS estimate in 3 of its last 3 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 100.2% below estimates on average.

The most recent 10 insider filings for Atlantic International Corp. break down as 0 sales and 10 purchases. On net that is roughly 9.6M shares acquired (about $11.6M) — insiders putting money in tends to read as conviction.

ATLN Financials

ATLN Latest News

What Investors Ask About Atlantic International Corp. (ATLN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources